Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D AnkerJaved ButlerGerasimos FilippatosJoão P FerreiraEdimar BocchiMichael BöhmHans-Peter Brunner-La RoccaDong-Ju ChoiVijay ChopraEduardo Chuquiure-ValenzuelaNadia GiannettiJuan Esteban Gomez-MesaStefan JanssensJames L JanuzziJose R Gonzalez-JuanateyBela MerkelyStephen J NichollsSergio V PerroneIleana L PiñaPiotr PonikowskiMichele SenniDavid SimJindrich SpinarIain SquireStefano TaddeiHiroyuki TsutsuiSubodh VermaDragos VinereanuJian ZhangPeter CarsonCarolyn Su Ping LamNikolaus MarxCordula ZellerNaveed SattarWaheed JamalSven SchnaidtJanet M SchneeMartina BrueckmannStuart J PocockFaiez ZannadMilton Packernull nullPublished in: The New England journal of medicine (2021)
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).